| MAyflOwer RoADA Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy | Donepezil, Galantamine, Memantine, Rivastigmine, RO4602522 Alzheimer’s disease | Alzheimer's disease | Ph 2 | Completed | 142 | Jun 2015 | 1 | |
| NCT00322153A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease | Memantine Alzheimer’s disease | Alzheimer's disease | Ph 3 | Completed | 83 | Oct 2007 | 1 | results |
| NCT02580305SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study | Donepezil, Masupirdine, Memantine Alzheimer’s disease | Alzheimer's disease | Ph 2 | Completed | 71 | Nov 2019 | 3 | results |
| NCT00857233Safety and Tolerability of Memantine in Moderate to Severe Alzheimer's Disease | Memantine Alzheimer’s disease | Study partner/caregiver required | Ph 3 | Terminated | 33 | Jul 2010 | - | results |
| NCT00469456Effect of Memantine on Functional Communication in Patients With Alzheimer's Disease | Memantine Alzheimer’s disease | Alzheimer's disease | Ph 4 | Completed | 25 | Nov 2008 | - | results |
| NCT00857649Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's Disease | Memantine Alzheimer’s disease | Alzheimer's disease | Ph 3 | Terminated | 23 | Apr 2010 | 1 | results |
| TEAM-ADA Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease | Memantine Alzheimer’s disease | Alzheimer's disease | Ph 3 | Completed | 14 | Sep 2012 | 2 | results |
| NCT01261741Investigation of Memantine in the Treatment of Memory, Concentration or Attention Problems | Memantine Mixed / unspecified dementia | Age 50-80 | Ph 2 | Completed | 14 | Aug 2011 | - | |
| NCT07251023Efficacy and Safety of DMB-I (INN: Latrepirdine) in Patients With Alzheimer Type Dementia | Dimebon, Memantine Alzheimer’s disease | mild-to-moderate AD | Ph 3 | Recruiting | 12 | May 2027 | - | |
| NCT00097916An Evaluation of the Safety and Efficacy of Memantine in Agitated Patients With Moderate to Severe Alzheimer's Disease | Memantine Alzheimer’s disease | AD symptomatic therapy: stable ≥3 months | Ph 3 | Completed | 9 | Apr 2006 | - | |
| NCT00545974Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia | Memantine Frontotemporal dementia | Symptomatic FTD | Ph 4 | Completed | 9 | Dec 2012 | 26 | results |
| NCT02553928Comparison of Once Daily and Twice Daily Dosing on Safety and Tolerability of Memantine in Patients With Alzheimer | Memantine Alzheimer’s disease | Alzheimer's disease | Ph 4 | Completed | 6 | Jul 2016 | - | results |
| NCT03316898A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease | AGN-242071, Donepezil, Memantine Alzheimer’s disease | Alzheimer's disease | Ph 1 | Withdrawn | 6 | Nov 2018 | - | |
| NCT07417670Satisfaction With Orodispersible vs Conventional Memantine in Moderate to Severe Alzheimer's Disease | Memantine Alzheimer’s disease | Alzheimer's disease | Ph 4 | Completed | 4 | Aug 2025 | 1 | |
| MINDLocal Study of Akatinol Memantine in VaD in Russia | Memantine Vascular cognitive impairment / dementia | Vascular dementia | Ph 3 | Completed | 4 | Jun 2022 | - | |
| MEMPDDEfficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB) | Memantine Lewy body dementia | Dementia with Lewy bodies | Ph 2 | Completed | 4 | Feb 2009 | - | |
| NCT00505167Memantine Versus Donepezil in Early Stages of Alzheimer's Disease | Donepezil, Memantine Alzheimer’s disease | Alzheimer's disease | Ph 4 | Completed | 3 | Jul 2008 | 1 | |
| WP3_P002Prediction of Cognitive Properties of Memantine for Neurodegenerative Diseases | Memantine Alzheimer’s disease | Age 18-30 | Ph 1 | Terminated | 3 | Dec 2020 | - | |
| MAGDMemantine for Agitation in Dementia | Memantine Alzheimer’s disease | Alzheimer's disease | Ph 4 | Completed | 2 | Jun 2009 | 1 | |
| NCT00401167Memantine for Agitation and Aggression in Severe Alzheimer's Disease | Memantine Alzheimer’s disease | Alzheimer's disease | Ph 4 | Completed | 2 | Jan 2010 | 1 | |
| NCT00240760Memantine and Down's Syndrome | Memantine Mixed / unspecified dementia | Age ≥18 | Not applicable | Unknown | 2 | - | - | |
| MONANTIMonitoring Anti-Dementia Drugs by Serum Levels | Donepezil, Memantine Alzheimer’s disease, Lewy body dementia | Multiple dementia etiologies | Ph 4 | Completed | 1 | Feb 2023 | 1 | results |
| NCT00624026Memantine - Communication Study | Memantine Alzheimer’s disease | Alzheimer's disease | Ph 3 | Completed | 1 | Dec 2008 | 1 | |
| NCT00594737Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia | Memantine Frontotemporal dementia | Age 40-80 | Ph 3 | Completed | 1 | Jun 2012 | 3 | |
| NCT00255086The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients | Memantine Alzheimer’s disease | MMSE 7-28 | Ph 3 | Completed | 1 | Jun 2009 | - | results |
